» Articles » PMID: 21377881

HIV Envelope: Challenges and Opportunities for Development of Entry Inhibitors

Overview
Date 2011 Mar 8
PMID 21377881
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

The HIV envelope proteins glycoprotein 120 (gp120) and glycoprotein 41 (gp41) play crucial roles in HIV entry, therefore they are of extreme interest in the development of novel therapeutics. Studies using diverse methods, including structural biology and mutagenesis, have resulted in a detailed model for envelope-mediated entry, which consists of multiple conformations, each a potential target for therapeutic intervention. In this review, the challenges, strategies and progress to date for developing novel entry inhibitors directed at disrupting HIV gp120 and gp41 function are discussed.

Citing Articles

The Glu143 Residue Might Play a Significant Role in T20 Peptide Binding to HIV-1 Receptor gp41: An In Silico Study.

Alaofi A Molecules. 2022; 27(12).

PMID: 35745059 PMC: 9229102. DOI: 10.3390/molecules27123936.


Peptide Triazole Inhibitors of HIV-1: Hijackers of Env Metastability.

Carter E, Ang C, Chaiken I Curr Protein Pept Sci. 2022; 24(1):59-77.

PMID: 35692162 PMC: 11660822. DOI: 10.2174/1389203723666220610120927.


Double Arylation of the Indole Side Chain of Tri- and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1 and EV-A71 Entry Inhibitors†.

Marti-Mari O, Martinez-Gualda B, de la Puente-Secades S, Mills A, Quesada E, Abdelnabi R J Med Chem. 2021; 64(14):10027-10046.

PMID: 34229438 PMC: 8389807. DOI: 10.1021/acs.jmedchem.1c00315.


Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors.

Curreli F, Ahmed S, Benedict Victor S, Iusupov I, Spiridonov E, Belov D Bioorg Med Chem. 2021; 32:116000.

PMID: 33461144 PMC: 7856678. DOI: 10.1016/j.bmc.2021.116000.


Structure, membrane topology and influence of cholesterol of the membrane proximal region: transmembrane helical anchor sequence of gp41 from HIV.

Aisenbrey C, Rifi O, Bechinger B Sci Rep. 2020; 10(1):22278.

PMID: 33335248 PMC: 7746737. DOI: 10.1038/s41598-020-79327-6.


References
1.
Sun Z, Oh K, Kim M, Yu J, Brusic V, Song L . HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity. 2008; 28(1):52-63. DOI: 10.1016/j.immuni.2007.11.018. View

2.
Jacobs A, Sen J, Rong L, Caffrey M . Alanine scanning mutants of the HIV gp41 loop. J Biol Chem. 2005; 280(29):27284-8. DOI: 10.1074/jbc.M414411200. View

3.
Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B . A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A. 2008; 105(10):3739-44. PMC: 2268799. DOI: 10.1073/pnas.0800255105. View

4.
Wingfield P, Stahl S, Kaufman J, Zlotnick A, Hyde C, Gronenborn A . The extracellular domain of immunodeficiency virus gp41 protein: expression in Escherichia coli, purification, and crystallization. Protein Sci. 1997; 6(8):1653-60. PMC: 2143772. DOI: 10.1002/pro.5560060806. View

5.
Sen J, Jacobs A, Jiang H, Rong L, Caffrey M . The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160. Protein Sci. 2007; 16(6):1236-41. PMC: 2206660. DOI: 10.1110/ps.072771407. View